# Which treatment claims can you trust? *Straight Treatment Claims — Orthobiologics Peoria* > Orthobiologics Peoria facts on what PRP may change, what it cannot prove, and why people can get different results. This page sorts honest treatment claims from promises that go too far. ## Can PRP rebuild my joint? PRP is made by drawing some of your blood, spinning it, and keeping one portion for the sore area. Some people say the ache eased afterward. Others don't. Feeling better doesn't prove that cartilage, the smooth cover on the ends of bones, grew back. An MRI can look the same even when movement feels easier. If I were paying, I'd want that difference said before I chose anything. ## Does improvement mean PRP caused it? Not always. A joint may settle because you did less, slept better, or used other care. In some tests, one set of people received PRP. The other received a plain salt-water shot. Researchers then checked how much each set improved. When the change is much the same, that test hasn't shown added help from PRP. Your relief still matters. It just can't tell you what caused the change. ## Why do PRP results sound so different? PRP isn't made the same way at every office. The amount of blood drawn and the portion kept can differ. The number of visits can differ too. Research on a mildly worn knee may not tell you much about a badly worn hip or a sore shoulder. Ask whether the test involved the same joint and about the same amount of wear. Here is the useful question: did that blood mixture help someone in my situation? ## What is a fair promise? A fair claim says that soreness or movement may improve, but it may not. It doesn't promise new cartilage. QC Kinetix medical providers, meaning the people who examine you, may discuss biologic therapies in Peoria, or care that starts with blood or tissue, after checking the sore area. They still can't know what will happen afterward. Uncertainty isn't an excuse here. It's part of an honest answer. ## Sources 1. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study. Whittle SL, et al. — [Stem cell injections for osteoarthritis of the knee.](https://pubmed.ncbi.nlm.nih.gov/40169165/). *Cochrane Database of Systematic Reviews*, 2025. DOI: 10.1002/14651858.CD013342.pub2. 2. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature Medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 4. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products. U.S. Food and Drug Administration — [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/consumer-alert-regenerative-medicine-products-including-stem-cells-and-exosomes). *FDA (Center for Biologics Evaluation and Research)*, 2020. 5. In a within-patient placebo-controlled trial, 25 people with BILATERAL knee osteoarthritis received bone marrow aspirate concentrate in one knee and saline in the other, acting as their own controls. Pain scores fell significantly from baseline in BOTH knees at 1 week, 3 months and 6 months, and the relief - described by the authors as dramatic - did not differ significantly between the BMAC knee and the saline knee. Shapiro SA, et al. — [A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/27566242/). *American Journal of Sports Medicine*, 2017. DOI: 10.1177/0363546516662455. 6. A phase III double-blind placebo-controlled trial of a SINGLE injection of culture-expanded autologous adipose-derived MSCs in 261 patients with KL grade 3 knee OA found significantly better VAS pain (25.2 vs 15.5 mm improvement; P=.004) and total WOMAC (21.7 vs 14.3; P=.002) at 6 months versus placebo, with no serious treatment-related adverse events - but MRI showed NO significant difference in cartilage-defect change between groups. Culture-expanded cells of this kind are a drug in the United States and are not available outside a trial. Kim KI, et al. — [Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.](https://pubmed.ncbi.nlm.nih.gov/37345256/). *American Journal of Sports Medicine*, 2023. DOI: 10.1177/03635465231179223. 7. A meta-analysis of the PLACEBO arms of 73 double-blind trials (5,895 patients) quantified what a saline knee injection alone achieves: statistically and clinically significant improvement in pain, function and quality of life at 1, 3 and 6 months, with responder rates exceeding 50% at all three time points, peaking around 4-8 months and declining by 12 months. Placebo response was stronger in trials with more female participants and in more recently published trials. Previtali D, et al. — [Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression.](https://pubmed.ncbi.nlm.nih.gov/41031623/). *EFORT Open Reviews*, 2025. DOI: 10.1530/EOR-2025-0022. 8. A cross-sectional study contacted 273 of 317 US centres offering direct-to-consumer stem-cell therapy, posing as a 57-year-old man with knee osteoarthritis. The mean advertised price of a unilateral same-day stem-cell knee injection was $5,156 (SD $2,446; 95% CI $4,550-5,762, n=65) and the mean claimed clinical efficacy was 82% (SD 9.6%; n=36) - a figure the authors describe as a gap between marketing claims and the published literature. Piuzzi NS, et al. — [The Stem-Cell Market for the Treatment of Knee Osteoarthritis: A Patient Perspective.](https://pubmed.ncbi.nlm.nih.gov/28738432/). *Journal of Knee Surgery*, 2018. DOI: 10.1055/s-0037-1604443. 9. An analysis of internet-based marketing claims found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the UNITED STATES - previously treated as a phenomenon of countries with lax medical regulation - and concluded that regulatory agencies must better oversee this marketplace. Turner L, Knoepfler P. — [Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry.](https://pubmed.ncbi.nlm.nih.gov/27374789/). *Cell Stem Cell*, 2016. DOI: 10.1016/j.stem.2016.06.007. 10. In January 2025 federal district court orders resolving a joint FTC and Georgia Attorney General complaint permanently BANNED the co-founders of the Stem Cell Institute of America and several related companies from marketing stem cell therapy, and required payment of $5,155,146 in civil penalties and consumer refunds. In March 2024 the court had granted summary judgment on all counts, finding the defendants created and published false and misleading advertisements about the efficacy of stem cell injections. The affiliated clinic charged up to $5,000 per injection, almost exclusively to elderly and disabled consumers. Federal Trade Commission — [Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties](https://www.ftc.gov/news-events/news/press-releases/2025/01/stem-cell-institute-co-founders-companies-banned-marketing-stem-cell-treatments-ordered-pay-more-51). *FTC Press Release*, 2025. 11. FDA's patient and consumer notice on regenerative medicine states that it has received reports of BLINDNESS, TUMOUR FORMATION, neurological events, bacterial infections including life-threatening blood infections, unwanted immune reactions, and cells migrating and forming unintended tissue, following the use of unapproved regenerative medicine products - a list that explicitly includes stromal vascular fraction, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes. It also warns that a product's presence on clinicaltrials.gov, or a firm's registration with FDA, does NOT mean the product is legally marketed. U.S. Food and Drug Administration — [Important Patient and Consumer Information About Regenerative Medicine Therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). *FDA (Center for Biologics Evaluation and Research)*, 2021. ## Would an exam help settle your questions? Write down your medicines and bring any X-ray report. Note where it hurts, which movement brings it on, and what has helped so far. The Peoria office is at 13128 N. 94th Dr., Suite 205, near Thunderbird Road west of Loop 101. Call (602) 837-PAIN. Schedule a free consultation: --- Straight talk about soreness and your choices. Orthobiologics Peoria answers about aching joints, care at home, warning signs, price, and a nearby clinic visit. Plain information about joint soreness, non-surgical choices, and local care in Peoria. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Peoria location; they benefit when a reader books with their clinic. © 2026 Peoria Joint Blueprint. General health education only; it does not diagnose a condition or replace care from a qualified clinician.